Creative Medical Technology Holdings Inc CELZ.OQ CELZ.O is expected to show no change in quarterly revenue when it reports results on November 6 (estimated) for the period ending September 30 2025
LSEG's mean analyst estimate for Creative Medical Technology Holdings Inc is for a loss of 48 cents per share.
The one available analyst rating on the shares is "buy".
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Creative Medical Technology Holdings Inc is $20.00, about 85% above its last closing price of $3.00
This summary was machine generated November 4 at 21:49 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)